You are here

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

Article type:

Original publication date: 
Saturday, July 29, 2017



The hallmark of chronic myeloid leukemia (CML) is the presence of Philadelphia chromosome, its resultant fusion transcript (BCR-ABL1), and fusion protein (p210). Alternate breakpoints in BCR (m-bcr, μ-bcr, and others) or ABL1 result in the expression of few rare fusion transcripts (e19a2, e1a2, e13a3, e14a3) and fusion proteins (p190, p200, p225) whose exact clinical significance remains to be determined.

Methods: Our studay was designed to determine the type and frequency of BCR-ABL1 fusion transcripts in 1260 CML patients and to analyse the prognosis and treatement response in patients harbouring rare BCR-ABL1 fustion transcripts. Read Abstract here and here